CYTK stock news · Cytokinetics, Incorporated
Get alerts for CYTK
Follow Cytokinetics, Incorporated (CYTK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CYTKCytokinetics is giving stock options and restricted shares to new employees as part of their hiring.
NeutralCytokinetics granted options for 64,110 shares and 42,496 restricted stock units to 18 new employees. These hiring awards do not change the company's outlook.
Cytokinetics shares the full details of their earnings call for the second quarter of 2026.
Good for CYTKCytokinetics reported Mycorzo sales growth, its first European launch, and successful aficamten trial results. The progress supports a brighter outlook, though regulators must still review aficamten.
Safety information from the pivotal trial is being evaluated by Cytokinetics investors.
NeutralCytokinetics announced positive primary results from its ACACIA-HCM Phase 3 clinical trial for aficamten, which showed significant improvements in symptoms and exercise performance in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, despite some concerns regarding heart failure events.
A $100 investment in Cytokinetics stock a decade ago would now yield this amount.
NeutralCytokinetics has shown a strong performance over the last decade, outperforming the market with an average annual return of 21.28%, leading to significant growth in investment value.